title: HE4 tissue expression in borderline ovarian tumors: a pilot study by the tumorbank ovarian cancer network.
abstract: OBJECTIVE
  Our purpose was to analyze the tissue expression of human epididymis protein-4 (HE4) in borderline tumors of the ovary (BOT) and to correlate it with histological subtypes and clinical features.
  
  
  METHODS
  Tumor tissue samples from 25 patients with BOT were stained on tissue microarrays. The percentage of stained tumor cells was represented by grouped immunoreactivity scores (IRS) 0 to 4.
  
  
  RESULTS
  The median patient age was 47 (range=22-73) years. Tumors in most patients (19/25) were staged-FIGO I and presented serous (52%) or mucinous (40%) histology. HE4 immunoreactivity occurred exclusively within the tumor cells. No association between grouped IRS and histological type, age, CA125 and FIGO stage was found. Correlation between HE4 positivity cells and HE4 IRS was significant (p<0.001).
  
  
  CONCLUSIONS
  The role of HE4 in BOT remains unclear. Multicenter surveys are needed to more profoundly help in the understanding of the biological and clinical features of BOT.
authors.affiliation: Department of Gynecology, Campus Virchow Clinic, Charité Medical University Berlin, Berlin, Germany. mani.nassir@charite.de
authors.forename: Mani
authors.initials: M
authors.lastname: Nassir
authors.forename: Silvia
authors.initials: S
authors.lastname: Darb-Esfahani
authors.forename: Rolf
authors.initials: R
authors.lastname: Richter
authors.forename: Radoslav
authors.initials: R
authors.lastname: Chekerov
authors.forename: Christina
authors.initials: C
authors.lastname: Hall
authors.forename: Mustafa Zelal
authors.initials: MZ
authors.lastname: Muallem
authors.forename: Carsten
authors.initials: C
authors.lastname: Denkert
authors.forename: Florin
authors.initials: F
authors.lastname: Stamatian
authors.forename: Christina
authors.initials: C
authors.lastname: Fotopoulou
authors.forename: Jalid
authors.initials: J
authors.lastname: Sehouli
authors.forename: Elena Ioana
authors.initials: EI
authors.lastname: Braicu
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000378:metabolism* / Q000473:pathology; D002288:Adenocarcinoma, Mucinous / Q000378:metabolism* / Q000473:pathology; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D018284:Cystadenocarcinoma, Serous / Q000378:metabolism* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000473:pathology; D010865:Pilot Projects; D011379:Prognosis; D011506:Proteins / Q000378:metabolism*; D015996:Survival Rate; D046888:Tissue Array Analysis; D000081102:WAP Four-Disulfide Core Domain Protein 2; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D011506:Proteins; D000081102:WAP Four-Disulfide Core Domain Protein 2; C569698:WFDC2 protein, human